ArticleJournal of gastrointestinal oncology2026
A prognostic nomogram based on log odds of positive lymph nodes to predict survival in gastric cancer patients with neoadjuvant chemotherapy: a large population-based cohort study and external validation.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy is the standard treatment for advanced gastric cancer (GC), yet a considerable proportion of patients gain no survival benefit and frequently present with regional lymph node metastasis. Few prognostic models have specifically incorporated lymph node-related parameters in this setting. The lymph node ratio (LNR) and the LODDS have been reported by several studies to have great predictive ability compared to LNR in patients with partial GC. In this study, we aimed to explore the potential value of various clinical features (including but not limited to LNR and LODDS) in predicting the outcomes of gastric cancer patients who receive systemic therapy before surgery. Methods: We retrospectively identified 726 GC patients who underwent neoadjuvant chemotherapy and subsequent surgery from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2019). Patients were randomly divided into a training cohort (n=510) and an internal validation cohort (n=216). An external validation cohort consisted of 124 patients from The First Affiliated Hospital of Wenzhou Medical University. Optimal cut-off values were determined using the Kaplan-Meier method. Univariate and multivariable logistic and Cox regression analyses were performed for variable screening. A prognostic nomogram incorporating independent risk factors was constructed and validated using the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves. Results: Primary tumor site, T stage, N stage, and log odds of positive lymph nodes (LODDS) were identified as independent prognostic factors and integrated into the nomogram. The nomogram yielded a C-index of 0.755 in the training cohort, 0.732 in the internal validation cohort, and 0.809 in the external validation cohort. The 1-, 3-, and 5-year areas under the curves (AUCs) were 0.780, 0.790, and 0.803 in the training cohort; 0.742, 0.730, and 0.752 in the internal validation cohort; and 0.747, 0.777, and 0.725 in the external validation cohort, respectively. Conclusions: LODDS is an independent prognostic indicator in GC patients receiving neoadjuvant chemotherapy. The newly developed nomogram provides accurate individualized survival prediction in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.